

Peppi Karppinen (international publication name P. KOIVUNEN)
Full List of Publications 1.8.2016

Peer-Reviewed Scientific Articles

1. Veijola J, **KOIVUNEN P**, Annunen P, Pihlajaniemi T, and Kivirikko KI (1994): Cloning, baculovirus expression, and characterization of the α subunit of prolyl 4-hydroxylase from the nematode *Caenorhabditis elegans*. This α subunit forms an active $\alpha\beta$ dimer with the human protein disulfide isomerase/ β subunit. *J. Biol. Chem.*, 269: 26746-26753.
2. **KOIVUNEN P**, Helaakoski T, Annunen P, Veijola J, Räisänen S, Pihlajaniemi T, and Kivirikko KI (1996): ERp60 does not substitute for protein disulfide isomerase as the β -subunit of prolyl 4-hydroxylase. *Biochem. J.*, 316: 599-605.
3. Veijola J, Annunen P, **KOIVUNEN P**, Page AP, Pihlajaniemi T, and Kivirikko KI (1996): Baculovirus expression of two protein disulphide isomerase isoforms from *Caenorhabditis elegans* and characterization of prolyl 4-hydroxylases containing one of these polypeptides as their β subunit. *Biochem. J.*, 317: 721-729.
4. **KOIVUNEN P**, Horelli-Kuitunen N, Helaakoski T, Karvonen P, Jaakkola M, Palotie A, and Kivirikko KI (1997): Structures of the human gene for the protein disulfide isomerase-related polypeptide ERp60 and a processed gene and assignment of these genes to 15q15 and 1q21. *Genomics*, 42: 397-404.
5. **KOIVUNEN P**, Pirneskoski A, Karvonen P, Ljung J, Helaakoski T, Notbohm H, and Kivirikko KI (1999): The acidic C-terminal domain of protein disulfide isomerase is not critical for the enzyme subunit function or for the chaperone or disulfide isomerase activities of the polypeptide. *EMBO J.*, 18: 65-74.
6. Annunen P, **KOIVUNEN P**, and Kivirikko KI (1999): Cloning of the α subunit of prolyl 4-hydroxylase from *Drosophila* and expression and characterization of the corresponding enzyme tetramer with some unique properties. *J. Biol. Chem.*, 274: 6790-6796.
7. Dijkstra K, Karvonen P, Pirneskoski A, **KOIVUNEN P**, Kivirikko KI, Darby NJ, van Straaten M, Sckeek RM, and Kemmink J (1999): Assignment of ^1H , ^{13}C and ^{15}N resonances of the a' domain of protein disulfide isomerase. *J. Biomol. NMR*, 14: 195-196.
8. Klappa P, **KOIVUNEN P**, Pirneskoski A, Karvonen O, Ruddock LW, Kivirikko KI, and Freedman RB (2000): Mutations that destabilize the a' domain of human protein-disulfide isomerase indirectly affect peptide binding. *J. Biol. Chem.*, 275: 13213-13218.
9. Pirneskoski A, Ruddock LW, Klappa P, Freedman RB, Kivirikko KI, and **KOIVUNEN P** (2001): Domains b' and a' of protein disulfide isomerase fulfill the minimum requirement for function as a subunit of prolyl 4-hydroxylase. The N-terminal domains a and b enhance this function and can be substituted in part by those of ERp57. *J. Biol. Chem.*, 276: 11287-11293.
10. Silvennoinen L, Karvonen P, **KOIVUNEN P**, Myllyharju J, Kivirikko KI, and Kilpeläinen I (2001): Assignment of ^1H , ^{13}C and ^{15}N resonances of the a' domain of ERp57. *J. Biomol. NMR*, 20: 385-386.
11. Ruoppolo M, Orrù S, Talamo F, Ljung J, Pirneskoski A, Kivirikko KI, Marino G, and **KOIVUNEN P** (2003): Mutations in domain a' of protein disulfide isomerase affect the folding pathway of bovine pancreatic ribonuclease A. *Prot. Sci.*, 12: 939-952.
12. Hirsilä M, **KOIVUNEN P**, Günzler V, Kivirikko KI, and Myllyharju J (2003): Characterization of human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. *J. Biol. Chem.*, 278: 30772-30780.

13. **KOIVUNEN P**, Hirsilä M, Günzler V, Kivirikko KI, and Myllyharju J (2004): Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. *J. Biol. Chem.*, 279: 9899-9904.
14. Silvennoinen L, Myllyharju J, Ruoppolo M, Orrù S, Caterino M, Kivirikko KI, and **KOIVUNEN P** (2004): Identification and characterization of structural domains of human ERp57. Association with calreticulin requires several domains. *J. Biol. Chem.*, 279: 13607-13615.
15. Russell SJ, Ruddock LW, Salo KEH, Oliver JD, Roebuck QP, Llewellyn DH, Roderick HL, **KOIVUNEN P**, Myllyharju J, and High S (2004): The primary substrate binding site in the *b'* domain of ERp57 is adapted for endoplasmic reticulum lectin association. *J. Biol. Chem.*, 279: 18861-18869.
16. Kukkola L, **KOIVUNEN P**, Pakkanen O, Page AP, and Myllyharju J (2004): Collagen prolyl 4-hydroxylase tetramers and dimers show identical decreases in K_m values for peptide substrates with increasing chain length. Mutation of one of the two catalytic sites in the tetramer inactivates the enzyme by more than half. *J. Biol. Chem.*, 279: 18656-18661.
17. Mayer M, Frey S, **KOIVUNEN P**, Myllyharju J, and Buchner J (2004): Influence of the oxidoreductase ERp57 on the folding of an antibody Fab fragment. *J. Mol. Biol.*, 341: 1077-1084.
18. Li D, Hirsilä M, **KOIVUNEN P**, Brenner MC, Xu L, Yang C, Kivirikko KI, and Myllyharju J (2004): Many amino acid substitutions in a HIF-1 α -like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases. Substitution of 3,4-dehydroproline or azetidine-2-carboxylic acid for the proline leads to a high rate of uncoupled 2-oxoglutarate decarboxylation. *J. Biol. Chem.*, 279: 55051-55059.
19. Tiainen P, Myllyharju J, and **KOIVUNEN P** (2005): Characterization of a second *Arabidopsis thaliana* prolyl 4-hydroxylase with distinct substrate specificity. *J. Biol. Chem.*, 280: 1142-1148.
20. **KOIVUNEN P**, Salo KEH, Myllyharju J, and Ruddock LW (2005): Three binding sites in protein disulfide isomerase co-operate in collagen prolyl 4-hydroxylase tetramer assembly. *J. Biol. Chem.*, 280: 5227-5235.
21. Hirsilä M, **KOIVUNEN P**, Xu L, Seeley T, Kivirikko KI, and Myllyharju J (2005): Effect of metals on the hydroxylases in the oxygen sensing pathway. Cobalt is only a weak inhibitor of HIF prolyl 4-hydroxylases, while cobalt and zinc are effective inhibitors of the asparaginyl hydroxylase. *FASEB J.*, 10: 1308-1310.
22. Silvennoinen L, **KOIVUNEN P**, Myllyharju J, Kilpeläinen I, and Permi P (2005): NMR assignment of the N-terminal domain *a* of the glycoprotein chaperone ERp57. *J. Biomol. NMR*, 33:136.
23. **KOIVUNEN P**, Hirsilä M, Kivirikko KI, and Myllyharju J (2006): The length of peptide substrates has a marked effect on hydroxylation by the HIF prolyl 4-hydroxylases. *J. Biol. Chem.*, 281: 28712-28720.
24. **KOIVUNEN P**, Hirsilä M, Remes AM, Kivirikko KI, and Myllyharju J (2007): Inhibition of HIF hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. *J. Biol. Chem.*, 282: 4524-4532.
25. **KOIVUNEN P**, Tiainen P, Hyvärinen J, Williams KE, Sormunen R, Klaus SJ, Kivirikko KI, and Myllyharju J (2007): An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on HIF- α . *J. Biol. Chem.*, 282: 30544-30552.
26. Koivunen J ja **KARPPINEN P** (2008): Syöpägenomiprojektit muuttamassa syövän diagnostiikkaa ja hoitoa. (in Finnish) *Duodecim*, 124: 2291-2293.
27. Wilkins SE¹, Hyvärinen J¹, Peet DJ, Bilton RL¹, and **KOIVUNEN P**¹ (2009): Differences in hydroxylation and binding of Notch and HIF-1 α demonstrate substrate selectivity for Factor Inhibiting HIF-1 (FIH-1). ¹Equal contribution. *Int. J. Biochem. Cell Biol.*, 41:1563-1571.

28. Hyvärinen J, Hassinen IE, Sormunen R, Mäki JM, Kivirikko KI, **KOIVUNEN P**¹, and Myllyharju J¹ (2010): Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against ischemia-reperfusion injury. ¹Equal contribution. *J. Biol. Chem.*, 285:13646-13657.
29. Hyvärinen J, Parikka M, Rämetsä M, Tryggvason K, Kivirikko KI, Myllyharju J, and **KOIVUNEN P** (2010): Deficiency of the novel transmembrane prolyl 4-hydroxylase in zebrafish leads to basement membrane defects and kidney failure. *J. Biol. Chem.*, 285: 42023-42032.
30. Peurala E, **KOIVUNEN P**¹, Bloigu R, Haapasaari K-M¹, and Jukkola-Vuorinen A¹ (2012): Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. ¹Equal contribution. *Breast Cancer Res. Treat.*, 133:179-188.
31. Taube E, Jokinen E, **KOIVUNEN P**, and Koivunen J (2012): A novel treatment strategy for EGFR-mutant NSCLC with T790M-mediated acquired resistance. *Int. J. Cancer*, 131: 970-979.
32. **KOIVUNEN P**¹, Lee S¹, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, Verhaak RGW, Yan H, and Kaelin WG Jr (2012): Transformation by the R enantiomer of 2-hydroxyglutarate linked to EglN activation. ¹Equal contribution. *Nature*, 483:484-488.
33. Haghighi Poodeh S, Salonurmi T, Nagy I, **KOIVUNEN P**, Vuoristo J, Räsänen J, Sormunen R, Vainio S, and Savolainen MJ (2012): Alcohol-induced premature permeability in mouse placenta-yolk sack barriers in vivo. A potential pathomechanism behind the fetal alcohol syndrome. *Placenta*, 33: 866-873.
34. Laitala A, Aro E, Walkinshaw G, Mäki JM, Rossi M, Heikkilä M, Savolainen E-R, Arend M, Kivirikko KI, **KOIVUNEN P**¹, and Myllyharju J¹ (2012): A transmembrane prolyl 4-hydroxylase is a fourth prolyl 4-hydroxylase regulating EPO production and erythropoiesis. ¹Equal contribution. *Blood*, 120: 3336-3344.
35. Peurala E, **KOIVUNEN P**, Haapasaari K-M, Bloigu R, and Jukkola-Vuorinen A (2013): The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. *Breast Cancer Res.*, 15: R5.
36. Losman JA, Looper RE, **KOIVUNEN P**, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, and Kaelin WG Jr (2013): (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. *Science*, 339: 1621-1625.
37. Palomäki S, Pietilä M, Laitinen S, Pesälä J, Sormunen R, Lehenkari P¹, and **KOIVUNEN P**¹ (2013): HIF-1 α is Upregulated in Human Mesenchymal Stem Cells. ¹Equal contribution. *Stem Cells*, 31: 1902-1909.
38. Kerkelä R, Karsikas S, Szabo Z, Serpi R, Magga J, Gao E, Alitalo K, Anisimov A, Sormunen R, Koch WJ, Kivirikko KI, Myllyharju J, and **KOIVUNEN P** (2013): Activation of hypoxia response in endothelial cells contributes to ischemic cardioprotection. *Mol. Cell. Biol.*, 33:3321-3329.
39. Myllyharju J, and **KOIVUNEN P** (2013): Hypoxia-inducible factor prolyl 4-hydroxylases: common and specific roles. *Biol. Chem.*, 394: 435-448.
40. Loukovaara S, **KOIVUNEN P**, Inglés M, Escobar J, Vento M, and Andersson S (2014): Elevated protein carbonyl and HIF-1 α levels in eyes with proliferative diabetic retinopathy. *Acta Ophthalmol.*, 92: 323-327.
41. Lorenzo FR¹, Huff C¹, Myllymäki M¹, Swierczek S, Ge R, Vankayalapati H, Xing J, Simonson T, Jorde LB, **KOIVUNEN P**², and Prchal JT² (2014): Missense mutation of the hypoxia inducible factor prolyl 4-hydroxylase 2 gene (p.D4E) experienced a strong positive selection in Tibetan highlanders. ^{1,2}Equal contribution. *Nat. Genet.*, 46: 951-956.
42. Rahtu-Korpela L, Karsikas S, Hörkkö S, Blanco Sequeiros R, Lammentausta E, Mäkelä KA, Herzog K-H, Walkinshaw G, Kivirikko KI, Myllyharju J, Serpi R, and **KOIVUNEN P** (2014):

HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction. *Diabetes*, 63: 3324-3320.

43. Zheng X, Zhai B, **KOIVUNEN P**, Shin SJ, Lu G, Liu J, Geisen C, Chakraborty AA, Moslehi JJ, Smalley DM, Wei X, Chen X, Chen Z, Beres JM, Zhang J, Tsao JL, Brenner MC, Zhang Y, Fan C, DePinho RA, Paik J, Gygi SP, Kaelin WG Jr, and Zhang Q (2014): Prolyl hydroxylation by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x deubiquitinase. *Genes Dev.*, 28:1429-1444.
44. Kaasinen E, Rahikkala E, **KOIVUNEN P**, Miettinen S, Wamelink MMC, Aavikko M, Palin K, Myllyharju J, Moilanen JS, Pajunen L, Karhu A, and Lauri A. Aaltonen (2014): Clinical characterization, genetic mapping and whole-genome sequence analysis of a novel autosomal recessive intellectual disability syndrome. *Eur. J. Med. Genet.*, 51: 543-551.
45. Jokinen E, Laurila N, **KOIVUNEN P**, and Koivunen J (2014): Combining targeted drugs to overcome and prevent resistance of solid cancers with some stem-like cell features. *Oncotarget*, 5: 9295-9307.
46. Komulainen T, Lodge T, Hinttala R, Bolszak M, Pietilä M, **KOIVUNEN P**, Hakkola J, Poulton J, Morten KJ, and Uusimaa J (2015):#Sodium valproate induces mitochondrial respiration dysfunction in HepG2 in vitro liver model. *Toxicology*, 331: 47-56.
47. Siegert I, Schödel J, Nairz M, Dettmer K, Schatz V, Kalucka J, Franke K, Schley G, Beneke A, Sutter J, Moll M, Hellerbrand C, Wielockx B, Katschinski DM, Lang R, **KOIVUNEN P**, Oefner PJ, Bogdan C, Weiss G, Willam C, and Jantsch J (2015): Ferritin-mediated iron sequestration stabilizes hypoxia-inducible factor-1 α upon LPS-activation in the presence of ample oxygen. *Cell Reports*, 13: 2048-2055.
48. Karsikas S, Myllymäki M, Heikkilä M, Sormunen R, Kivirikko KI, Myllyharju J, Serpi R, and **KOIVUNEN P** (2016): HIF-P4H-2 Deficiency Protects Against Skeletal Muscle Ischemia-reperfusion Injury In a Mouse Hind Limb Ischemia Model. *J. Mol. Med.*, 94: 301-310.
49. **KOIVUNEN P**, Fell SM, Lu W, Rabinowitz JD, Kung AL, and Schlisio S (2016): The 2-oxoglutarate analogue 3-oxoglutarate decreases normoxic HIF-1a in cancer cells, induces cell death and reduces tumor xenograft growth. *Hypoxia*, 4: 15-27.
50. Laukka T, Mariani CJ, Ithantola T, Cao JZ, Kaelin WG Jr, Godley LA, and **KOIVUNEN P** (2016): Fumarate and succinate regulate expression of hypoxia-inducible genes via TETs. *J. Biol. Chem.*, 291: 4256-4265.
51. Rahtu-Korpela L, Määttä J, Dimova EY, Hörkkö S, Gylling H, Walkinshaw G, Hakkola J, Kivirikko KI, Myllyharju J, Serpi R, and **KOIVUNEN P** (2016): Hypoxia-inducible factor prolyl 4-hydroxylase-2 inhibition protects against development of atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.*, 36: 608-617.
52. Halt K, Pärssinen H, Junttila S, Saarela U, Sims-Lucas S, **KOIVUNEN P**, Myllyharju J, Quaggin S, Skovorodkin I, and Vainio SJ (2016): CD146⁺ cells are essential for kidney vasculature development. *Kidney Int.*, 90: 311-324.
53. Briggs KJ, **KOIVUNEN P**, Cao S, Backus KM, Olenchock BA, Patel H, Zhang Q, Signoretti S, Gerfen GJ, Richardson AL, Witkiewicz AK, Cravatt BF, Clardy J, and Kaelin WG Jr (2016): Paracrine Induction of HIF by Glutamate in Triple-Negative Breast Cancer: EglN1 Senses Cysteine. *Cell*, 166: 126-139.
54. Leinonen H¹, Rossi M¹, Salo AM, Tiainen P, Hyvärinen J, Sormunen R, Miinalainen I, Zhang C, Soininen R, Kivirikko KI, Pitkänen M, Koskelainen A, Tanila H, Myllyharju J.², and **KOIVUNEN P**² (2016): Lack of P4H-TM results in age-related retinal and renal alterations in mice. ^{1,2}Equal contribution. *Hum. Mol. Genet.*, Jul 27. Pii:ddw228. PMID: 27466183.

55. Myllymäki MNM, Määttä J, Dimova EY, Izzi V, Väisänen T, Myllyharju J, **KOIVUNEN P**¹, and Serpi R¹ (2016): EPO-independent extramedullary erythropoiesis in spleen of HIF prolyl 4-hydroxylase-2 deficient mice. ¹Equal contribution. *Submitted to J Exp Med*.
56. Peurala E, **KOIVUNEN P**, Haapasaari K-M, Kauppila S, Karihtala P, Auvinen P, Soini Y, Bloigu R, and Jukkola-Vuorinen A (2016): Prognostic significance of hypoxia response and cell cycle regulators in triple-negative breast cancer. *Submitted to The Breast*.
57. Sharma U¹, Carrique L¹, Vadon-Le Goff S¹, Mariano N, Georges R-N, Delolme F, **KOIVUNEN P**, Myllyharju J, Moali C, Aghajari N², Hulmes DJS² (2016): Why collagen I is normally a heterotrimer. ^{1,2}Equal contribution. *Submitted to Nature Communications*.

Non-Refereed Scientific Articles

58. **KOIVUNEN P**, Veijola J, Annunen P, Pihlajaniemi T, and Kivirikko KI (1994): Dimer of nematode alpha and human beta subunit functions as prolyl 4-hydroxylase. *Matrix Biol.*, 14: 360.
59. Lorenzo FR¹, Huff C¹, Myllymäki M¹, Swierczek S, Salama ME, Semenza GL, Gordeuk VR, Jorde L, **KOIVUNEN P**², and Prchal JT² (2012): A novel EGLN1/PHD2 high-frequency variant in Tibetans protects against hypoxia-induced polycythemia. ^{1,2}Equal contribution. *Blood*, 120: Meeting abstract 2079.
60. **KARPPINEN P** (2014): Geenimuutos mahdollistaa vuoristossa elämisen. *Duodecim*, 130: 2040.
61. **KARPPINEN P** (2015): Kasvaimen immuunijärjestelmän solut ja matkustajamutaatiot määrittämässä herkkyyttä uusille immunologisille syöpälääkkeille. *Duodecim*, 131: 513.
62. **KARPPINEN P** (2015): Ihmisalkion genomia muunneltu CRISPR/Cas-menetelmällä. *Duodecim*, 131: 1427.
63. **KARPPINEN P** (2016): Etäinen iskeeminen esialtistus ja sydänkirurgia – suojaa vai ei? *Duodecim*, 132: 19.
64. **KARPPINEN P** (2016): Uusi erytrotrofoni-hormoni on raudan säätelyn puuttuva linkki. *Duodecim*, 132: 1003.

Publications Intended For Professional Communities

65. **KARPPINEN P** (2010): Entsyymit elimistön hypoksiavasteessa. *Kliinlab.*, 4: 60-62.

Theses

66. **Karppinen née KOIVUNEN P** (1997): Prolyl 4-hydroxylase, its catalytically active α subunit, the multifunctional protein disulfide isomerase/ β subunit and a PDI-related polypeptide ERp60. *Acta Universitatis Ouluensis Medica*, D 409.

Patents and Invention Disclosures

67. Inventor in: Improved Methods for Treating Anemia. *U.S. Patent Application Serial No. 13/587,74*. Filed 18.8.2013.